Skip to main content
PO

PLU Ophthalmic

PLU Ophthalmic develops a minimally invasive glaucoma surgery technology that utilizes precise micro-excision techniques to enhance surgical efficacy while reducing risks associated with traditional procedures. This approach addresses the limitations of current glaucoma treatments, which often force surgeons to choose between effectiveness and safety, ultimately improving patient outcomes and operational efficiency.

Chicago, United StatesFounded 20233200+ followers
Updated 4 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Current glaucoma surgical treatments often force surgeons to choose between efficacy and safety, with traditional interventions carrying significant risks and minimally invasive glaucoma surgeries (MIGS) offering less than ideal efficacy. This lack of an ideal treatment necessitates a solution that combines high efficacy with superior safety.

Solution

PLU Ophthalmic develops a next-generation glaucoma surgery technology that utilizes precise micro-excision techniques to enhance surgical efficacy while reducing risks associated with traditional procedures. This minimally invasive, implant-free approach aims to improve patient outcomes and operational efficiency by eliminating the need to compromise between efficacy and safety. The technology offers a seamless, easy-to-use solution that simplifies patient management. By moving beyond traditional, complex, and risky surgeries while outperforming MIGS with higher effectiveness, PLU Ophthalmic provides a superior alternative for glaucoma surgical care.

Target Audience

The primary target audience includes ophthalmic surgeons specializing in glaucoma treatment, as well as hospitals and surgical centers seeking to improve patient outcomes and operational efficiency in glaucoma surgery.

Features

  • Minimally invasive glaucoma surgery utilizing precise micro-excision technology
  • Implant-free procedure
  • Aims for superior outcomes without the current trade-off between efficacy and safety
  • Shorter surgical times
  • Ease of use with minimal learning curve
  • Higher OR throughput
  • Reduced post-operative patient management
This profile is AI-generated and may contain inaccuracies.